Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRTX NASDAQ:DNLI NASDAQ:EDIT NASDAQ:FATE NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRTXCortexyme$1.62+1.3%$1.69$1.78▼$40.66$48.85M1.4620,672 shs555,023 shsDNLIDenali Therapeutics$13.63+2.8%$14.55$10.57▼$33.33$2.00B1.231.48 million shs791,595 shsEDITEditas Medicine$2.80-1.2%$2.74$0.91▼$4.12$250.43M2.162.76 million shs432,057 shsFATEFate Therapeutics$0.99+4.4%$1.09$0.66▼$4.20$115.91M2.211.96 million shs402,388 shsRGNXREGENXBIO$9.36+1.1%$8.78$5.03▼$13.15$472.47M1.17918,516 shs58,197 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRTXCortexyme0.00%+1.91%-5.33%+17.65%+117.69%DNLIDenali Therapeutics+0.76%-13.67%-9.80%-5.89%-56.28%EDITEditas Medicine+5.99%+2.54%-6.60%+20.43%-26.11%FATEFate Therapeutics-0.53%-2.98%-12.78%-21.43%-75.99%RGNXREGENXBIO+1.87%-6.37%+4.99%+8.05%-27.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRTXCortexyme$1.62+1.3%$1.69$1.78▼$40.66$48.85M1.4620,672 shs555,023 shsDNLIDenali Therapeutics$13.63+2.8%$14.55$10.57▼$33.33$2.00B1.231.48 million shs791,595 shsEDITEditas Medicine$2.80-1.2%$2.74$0.91▼$4.12$250.43M2.162.76 million shs432,057 shsFATEFate Therapeutics$0.99+4.4%$1.09$0.66▼$4.20$115.91M2.211.96 million shs402,388 shsRGNXREGENXBIO$9.36+1.1%$8.78$5.03▼$13.15$472.47M1.17918,516 shs58,197 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRTXCortexyme0.00%+1.91%-5.33%+17.65%+117.69%DNLIDenali Therapeutics+0.76%-13.67%-9.80%-5.89%-56.28%EDITEditas Medicine+5.99%+2.54%-6.60%+20.43%-26.11%FATEFate Therapeutics-0.53%-2.98%-12.78%-21.43%-75.99%RGNXREGENXBIO+1.87%-6.37%+4.99%+8.05%-27.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRTXCortexyme 0.00N/AN/AN/ADNLIDenali Therapeutics 3.12Buy$33.50145.78% UpsideEDITEditas Medicine 2.23Hold$5.1082.47% UpsideFATEFate Therapeutics 2.14Hold$3.30232.33% UpsideRGNXREGENXBIO 2.83Moderate Buy$28.38203.12% UpsideCurrent Analyst Ratings BreakdownLatest DNLI, FATE, RGNX, CRTX, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$52.009/8/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/5/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/3/2025EDITEditas MedicineWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$3.00 ➝ $4.008/19/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.008/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/15/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $5.008/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $6.008/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.508/8/2025RGNXREGENXBIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$21.00 ➝ $17.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/ADNLIDenali Therapeutics$330.53M6.03N/AN/A$8.53 per share1.60EDITEditas Medicine$32.31M7.78N/AN/A$1.63 per share1.71FATEFate Therapeutics$13.63M8.40N/AN/A$2.80 per share0.35RGNXREGENXBIO$83.33M5.67N/AN/A$5.24 per share1.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/ADNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)EDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.44N/AN/AN/A-112.70%-66.95%-34.14%11/5/2025 (Estimated)Latest DNLI, FATE, RGNX, CRTX, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 million8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/7/2025Q2 2025RGNXREGENXBIO-$1.13-$1.38-$0.25-$1.38$40.87 million$21.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRTXCortexymeN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRTXCortexymeN/A9.929.92DNLIDenali Therapeutics0.0110.2710.27EDITEditas MedicineN/A2.772.77FATEFate TherapeuticsN/A8.048.04RGNXREGENXBION/A3.133.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRTXCortexyme63.18%DNLIDenali Therapeutics92.92%EDITEditas Medicine71.90%FATEFate Therapeutics97.54%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipCRTXCortexyme27.90%DNLIDenali Therapeutics12.50%EDITEditas Medicine1.90%FATEFate Therapeutics5.51%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableEDITEditas Medicine23089.92 million88.21 millionOptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableRGNXREGENXBIO37050.51 million44.05 millionOptionableDNLI, FATE, RGNX, CRTX, and EDIT HeadlinesRecent News About These CompaniesREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 15 at 2:25 AM | marketbeat.comCurran Simpson Sells 7,734 Shares of REGENXBIO (NASDAQ:RGNX) StockSeptember 13, 2025 | insidertrades.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 13, 2025 | americanbankingnews.com405,281 Shares in REGENXBIO Inc. $RGNX Bought by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at HC WainwrightSeptember 10, 2025 | marketbeat.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan CapitalSeptember 10, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Earns Buy Rating from HC WainwrightSeptember 10, 2025 | americanbankingnews.comChardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)September 10, 2025 | americanbankingnews.comA Glimpse Into The Expert Outlook On Regenxbio Through 6 AnalystsSeptember 9, 2025 | benzinga.comRegenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter SyndromeSeptember 9, 2025 | seekingalpha.comREGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.com50,969 Shares in REGENXBIO Inc. $RGNX Purchased by Ieq Capital LLCSeptember 8, 2025 | marketbeat.comInvesco Ltd. Purchases 27,341 Shares of REGENXBIO Inc. $RGNXSeptember 7, 2025 | marketbeat.comREGENXBIO reports positive data from Hunter syndromeSeptember 6, 2025 | msn.comRegenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trialSeptember 6, 2025 | msn.comRegenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter SyndromeSeptember 6, 2025 | seekingalpha.comREGENXBIO Inc. $RGNX Shares Acquired by PDT Partners LLCSeptember 6, 2025 | marketbeat.comREGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS IISeptember 5, 2025 | prnewswire.comTrexquant Investment LP Purchases 308,516 Shares of REGENXBIO Inc. $RGNXSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 162,423 Shares of REGENXBIO Inc. $RGNXSeptember 4, 2025 | marketbeat.comHsbc Holdings PLC Sells 29,002 Shares of REGENXBIO Inc. $RGNXSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNLI, FATE, RGNX, CRTX, and EDIT Company DescriptionsCortexyme NASDAQ:CRTX$1.62 +0.02 (+1.25%) As of 09/16/2025Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Denali Therapeutics NASDAQ:DNLI$13.63 +0.37 (+2.79%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$2.80 -0.04 (-1.24%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Fate Therapeutics NASDAQ:FATE$0.99 +0.04 (+4.45%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.REGENXBIO NASDAQ:RGNX$9.36 +0.10 (+1.09%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
